Trepicchio named president of Publicis Healthcare’s North American advertising

Share this article:
Publicis Healthcare Communications Group (PHCG) has promoted Mike Trepicchio to the role of president, North America advertising. Yesterday was the first day on the job for Trepicchio, who spent the past two years as president of the Saatchi & Saatchi Healthcare Communications Group. In his new role, Trepicchio will be responsible for PHCG units Medicus New York, Medicus Canada, the Nelson Group (LifeBrands and Brand Pharm), Williams Labadie, Publicis Wellcare and Discovery Canada. Additionally, Trepicchio will continue his role as head of Saatchi & Saatchi Healthcare Communications Group, he said. Trepicchio told MM&M he plans to spend the next month evaluating how things operate before deciding whether or not to implement any changes. “It will probably take another 30 days or so to figure out,” he said. Meanwhile, PHCG president/COO Nick Collucci has taken on additional responsibilities for the international business, Trepicchio said. Collucci, who was traveling in Europe, was unavailable for comment at press time.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...